Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2170)
All Articles published online
|
Apr 21, 2009 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Francesco VD, Ierardi E, Hassan C, Zullo A. Furazolidone therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i15/1914.htm |
| Number | Citing Articles |
| 1 |
C. Chiesa, L. Pacifico, C. Anania, E. Poggiogalle, F. Chiarelli, J.F. Osborn. Helicobacter Pylori Therapy in Children: Overview and Challenges. International Journal of Immunopathology and Pharmacology 2010; 23(2): 405 doi: 10.1177/039463201002300203
|
| 2 |
Rahim Raoufi Jahromi, Jamal Mirzaei, Jalil Rajabi, Seyed Javad Hoseini Shokouh, Taraneh Liaghat. Furazolidone-Based Quadruple Therapy for Eradication of Helicobacter pylori Infection in Peptic Ulcer Disease. Archives of Clinical Infectious Diseases 2014; 9(3) doi: 10.5812/archcid.18549
|
| 3 |
Sotirios Georgopoulos, Vasilios Papastergiou. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 2021; 22(6): 729 doi: 10.1080/14656566.2020.1845649
|
| 4 |
Ya-Wen Zhang, Wei-Ling Hu, Yuan Cai, Wen-Fang Zheng, Qin Du, John J Kim, John Y Kao, Ning Dai, Jian-Min Si. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for <i>Helicobacter pylori</i> infection and predictors of failed eradication. World Journal of Gastroenterology 2018; 24(40): 4596-4605 doi: 10.3748/wjg.v24.i40.4596
|
| 5 |
Hidekazu Suzuki, Toshihiro Nishizawa, Toshifumi Hibi.
Helicobacter Pylori
Eradication Therapy
. Future Microbiology 2010; 5(4): 639 doi: 10.2217/fmb.10.25
|
| 6 |
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 2009; 18(11) doi: 10.1002/pds.1654
|
| 7 |
Javier P. Gisbert. Review: Second-line rescue therapy of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2009; 2(6): 331 doi: 10.1177/1756283X09347109
|
| 8 |
Keerthika Devi Ramadhass, Muthusankar Ganesan, Tse-Wei Chen, Shen-Ming Chen, Qingli Hao, Wu Lei, Gopu Gopalakrishnan. Porous-coral-like cerium doped tungsten oxide/graphene oxide micro balls: A robust electrochemical sensing platform for the detection of antibiotic residue. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2021; 628: 127275 doi: 10.1016/j.colsurfa.2021.127275
|
| 9 |
Jiali Zhang, Chunling Rong, Chenyang Yan, Jie Chen, Wenjun Yang, Lingyan Yu, Haibin Dai, Muhammad Shahzad Aslam. Risk factors of furazolidone-associated fever. PLOS ONE 2022; 17(4): e0266763 doi: 10.1371/journal.pone.0266763
|
| 10 |
Hansa Y. Magee, Megan M. Maurer, April Cobos, Benny F.G. Pycke, Arjun K. Venkatesan, Daniel Magee, Matthew Scotch, Rolf U. Halden. U.S. nationwide reconnaissance of ten infrequently monitored antibiotics in municipal biosolids. Science of The Total Environment 2018; 643: 460 doi: 10.1016/j.scitotenv.2018.06.206
|
| 11 |
Shivaram Prasad Singh, Vineet Ahuja, Uday C. Ghoshal, Govind Makharia, Usha Dutta, Showkat Ali Zargar, Jayanthi Venkataraman, Amit Kumar Dutta, Asish K Mukhopadhyay, Ayaskanta Singh, Babu Ram Thapa, Kim Vaiphei, Malathi Sathiyasekaran, Manoj K. Sahu, Niranjan Rout, Philip Abraham, Prakash Chandra Dalai, Pravin Rathi, Saroj K. Sinha, Shobna Bhatia, Susama Patra, Ujjala Ghoshal, Ujjal Poddar, Venigalla Pratap Mouli, Vikram Kate. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian Journal of Gastroenterology 2021; 40(4): 420 doi: 10.1007/s12664-021-01186-4
|
| 12 |
Jay Luther, William D. Chey, Richard J. Saad. A Clinician's Guide to Salvage Therapy for PersistentHelicobacter pyloriInfection. Hospital Practice 2011; 39(1): 133 doi: 10.3810/hp.2011.02.383
|
| 13 |
Kláudia Maria Machado Neves Silva, Diogo Émerson Leite de Carvalho, Vânia Maria Moreira Valente, Juan Carlos Campos Rubio, Paulo Eustáquio Faria, Priscila Pereira Silva-Caldeira. Concomitant and controlled release of furazolidone and bismuth(III) incorporated in a cross-linked sodium alginate-carboxymethyl cellulose hydrogel. International Journal of Biological Macromolecules 2019; 126: 359 doi: 10.1016/j.ijbiomac.2018.12.136
|
| 14 |
Javier P. Gisbert, Javier Molina-Infante, Alicia C. Marin, Gemma Vinagre, Jesus Barrio, Adrian Gerald McNicholl. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicateH. pyloriinfection. Scandinavian Journal of Gastroenterology 2013; 48(6): 652 doi: 10.3109/00365521.2013.786132
|
| 15 |
Lyudmila Boyanova, Ivan Mitov. Geographic map and evolution of primaryHelicobacter pyloriresistance to antibacterial agents. Expert Review of Anti-infective Therapy 2010; 8(1): 59 doi: 10.1586/eri.09.113
|
| 16 |
Yanhui Yu, Jing Xue, Fangbing Lin, Daming Liu, Wen Zhang, Shuying Ru, Feng Jiang. Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta‐Analysis. Helicobacter 2024; 29(3) doi: 10.1111/hel.13103
|